

# Onalespib

**Catalog No: tcsc0969**



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

912999-49-6

**Formula:**

$C_{24}H_{31}N_3O_3$

**Pathway:**

Metabolic Enzyme/Protease;Cell Cycle/DNA Damage

**Target:**

HSP;HSP

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 33$  mg/mL (80.58 mM)

**Alternative Names:**

AT13387

**Observed Molecular Weight:**

409.52


## Product Description

Onalespib (AT13387) is a potent inhibitor of **Hsp90**, with a **K<sub>d</sub>** of 0.71 nM.

IC50 & Target: Kd: 0.71 nM (Hsp90)<sup>[1]</sup>

***In Vitro:*** Onalespib (Compound 35) is a potent inhibitor of Hsp90, with K<sub>d</sub> of 0.71 nM. Onalespib shows potent antiproliferative activity in HCT116 cells, with an IC<sub>50</sub> of 31 nM. Onalespib also strongly inhibits the proliferation of a panel of human tumor cell lines, showing IC<sub>50</sub> of [1]. Onalespib exhibits cytotoxic activity against many of the PPTP cell lines, with median IC<sub>50</sub> of 41 nM<sup>[2]</sup>.

***In Vivo:*** Onalespib (60 mg/kg, ip 3 days on and 3 days off for four cycles) shows antitumor activity in nude BALB/c mice bearing early stage HCT116 human colon carcinoma xenografts<sup>[1]</sup>. Onalespib (40 or 60 mg/kg, i.p.) induces significant differences in EFS distribution compared to controls in 17% evaluable solid tumor xenografts, but in none of the ALL xenografts<sup>[2]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!